Post Menopausal Osteoporosis Market Expected to Reach US$ 15.2 billion by 2031 | Sandoz Group AG, Pfizer Inc., Amgen Inc., Novartis AG, AbbVie Inc

Post Menopausal Osteoporosis Market reached US$ 9.9 billion in 2023 and is expected to reach US$ 15.2 billion by 2031 growing with a CAGR of 5.4% during the forecast period 2024-2031.

The Post Menopausal Osteoporosis Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://datamintelligence.com/download-sample/post-menopausal-osteoporosis-market?sg

Post Menopausal Osteoporosis Market Landscape Analysis:

Postmenopausal osteoporosis refers to the medical focus on preventing, diagnosing, and managing osteoporosis in women following menopause. This condition is marked by a loss of bone strength and an increased likelihood of fractures, largely driven by hormonal shifts that occur during menopause-most notably, a sharp decline in estrogen levels.

As estrogen plays a key role in maintaining bone density, its reduction accelerates bone resorption, leading to a significant drop in bone mineral density (BMD). According to the World Health Organization (WHO), osteoporosis is clinically diagnosed when a woman's BMD is 2.5 standard deviations or more below the average of a healthy young adult. This decline makes postmenopausal women particularly vulnerable to fractures, as their bones become increasingly fragile over time.

Post Menopausal Osteoporosis Market: Shifting Industry Trends and Market Potential

Aging Population and Rising Osteoporosis Prevalence Drive Market Demand

The growing global prevalence of postmenopausal osteoporosis is largely driven by two key factors: the rapidly aging population and the increasing incidence of osteoporosis among older adults, particularly women. As the world's population ages, the number of women entering the postmenopausal stage-when the risk of osteoporosis significantly rises-is increasing at an unprecedented rate.

According to World Health Organization (WHO) data from October 2022, approximately 1 billion people worldwide were aged 60 or older in 2020. This number is expected to rise to 1.4 billion by 2030, accounting for one in every six individuals globally. By 2050, the population aged 60 and above is projected to surpass 2.1 billion, more than doubling from 2020 figures. This demographic shift has substantial implications for the demand for osteoporosis screening, prevention, and treatment.

Osteoporosis is a widespread condition marked by decreased bone mass and deterioration of bone quality, which heightens the risk of fractures. The WHO defines osteoporosis based on bone mineral density (BMD) readings, with a diagnosis made when BMD is 2.5 standard deviations or more below the average for healthy young women.

Recent research published by BMJ Yale in April 2024 highlights the gender disparity in osteoporosis prevalence, estimating it at 23.1% among women compared to 11.7% in men. This difference is largely attributed to the hormonal shifts that occur during menopause, particularly the decline in estrogen, which accelerates bone loss in women.

Together, these trends underscore a growing need for targeted interventions and therapeutic solutions within the postmenopausal osteoporosis market, as healthcare systems prepare to support an expanding aging population at heightened risk for bone-related conditions.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/post-menopausal-osteoporosis-market?sg

Strategic Players Driving the Post Menopausal Osteoporosis Market Forward: Sandoz Group AG, Pfizer Inc., Amgen Inc., Novartis AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Ambio Inc., and GSK plc.

Research Methodology:

The global Post Menopausal Osteoporosis Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Post Menopausal Osteoporosis Market:

By Drug Class (Bisphosphonates, RANK Ligand Inhibitors (Denosumab), Selective Estrogen Receptor Modulator (SERM) (Raloxifene), Monoclonal Antibody (Romosozumab), Parathyroid Hormone Analog, Calcitonin, Strontium, Anti-Sclerostin, Cathepsin K Inhibitors (CatK), Others)

By Route of Administration (Oral, Parenteral, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Regional Analysis for Post Menopausal Osteoporosis Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Post Menopausal Osteoporosis Market Research Industry:

➠ Who leads the Post Menopausal Osteoporosis industry and what's their competitive positioning regarding capacity, performance, and profitability?

➠ What growth opportunities and market challenges do Post Menopausal Osteoporosis market vendors face?

➠ Which segments show the highest growth potential and market share distribution?

➠ What factors are driving or limiting Post Menopausal Osteoporosis market growth?

➠ What are the dominant sales and distribution strategies in the Post Menopausal Osteoporosis industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.